Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunovant, Inc. - Common Stock (NQ:IMVT)

15.86 +0.55 (+3.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,232,112
Open 15.32
Bid (Size) 15.00 (5)
Ask (Size) 18.78 (3)
Prev. Close 15.31
Today's Range 15.11 - 15.93
52wk Range 12.72 - 34.47
Shares Outstanding 114,998,871
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Immunovant Stock Rises On Narrower-Than-Expected Q1 Loss: Retail’s Still On The Fence
The clinical-stage immunology company reported a net loss of $0.64 per share for the quarter, lower than an estimated loss of $0.72 per share. 
Via Stocktwits
IMVT INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm
From Robbins Geller Rudman & Dowd LLP
Via Business Wire

Performance

YTD
-37.0%
-37.0%
1 Month
+7.9%
+7.9%
3 Month
-16.0%
-16.0%
6 Month
-39.6%
-39.6%
1 Year
-39.4%
-39.4%

More News

Read More
Charles Schwab To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Four Stocks To Watch This Week - Monday, Sep. 23
Via Talk Markets
Top 2 Health Care Stocks That May Collapse This Quarter
Via Benzinga
Immunovant Crumbles After Roivant Sweeps Out Its C-Suite, Unveils Strategic Shift
Via Investor's Business Daily
Topics Government
Exposures Political
Immunovant Announces Roivant President Eric Venker As New CEO: Retail’s Elated
Via Stocktwits
Topics Government Retirement Stocks
Exposures Pension Political US Equities
Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402
From Roivant Sciences
Via GlobeNewswire
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data
Via Benzinga
Exposures Product Safety
Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Biohaven Slumps, Again, As Bipolar Setback Outweighs A $4 Billion Opportunity
Via Investor's Business Daily
High Frequency Trading, PPI Misreads Helped Fuel a Short Squeeze... Now What
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
Via Investor's Business Daily
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Via Benzinga
Roivant Provides Update on Graves’ Disease Development Program
From Roivant Sciences
Via GlobeNewswire
After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay
Via Investor's Business Daily
IMVT Stock Earnings: Immunovant Misses EPS for Q4 2024
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Biohaven Stock Stumbles As Protein-Degrading Drug Falls Short Of Expectations In Early-Stage Study
Via Benzinga
Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Heico Posts Upbeat Earnings, Joins Surmodics, Abercrombie & Fitch And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump
Via Investor's Business Daily
Wall Street’s Favorite Biotech Stocks? 3 Names That Could Make You Filthy Rich
Via InvestorPlace
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Via Investor's Business Daily

Frequently Asked Questions

Is Immunovant, Inc. - Common Stock publicly traded?
Yes, Immunovant, Inc. - Common Stock is publicly traded.
What exchange does Immunovant, Inc. - Common Stock trade on?
Immunovant, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Immunovant, Inc. - Common Stock?
The ticker symbol for Immunovant, Inc. - Common Stock is IMVT on the Nasdaq Stock Market
What is the current price of Immunovant, Inc. - Common Stock?
The current price of Immunovant, Inc. - Common Stock is 15.86
When was Immunovant, Inc. - Common Stock last traded?
The last trade of Immunovant, Inc. - Common Stock was at 06/18/25 04:00 PM ET
What is the market capitalization of Immunovant, Inc. - Common Stock?
The market capitalization of Immunovant, Inc. - Common Stock is 1.82B
How many shares of Immunovant, Inc. - Common Stock are outstanding?
Immunovant, Inc. - Common Stock has 2B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.